suppressing function in inhibiting cell proliferation, invasion and migration.
INTRODUCTION AND OBJECTIVES: Circular RNAs (circRNAs) represent a class of endogenous noncoding RNAs that have recently been recognized as important regulators of gene expression and pathological networks. However, the characterization and function of circRNAs in primary metastatic clear cell renal cell carcinoma (ccRCC) remain elusive.
METHODS: We investigated the expression profile of circRNAs in five primary metastatic and five non-metastatic ccRCC tumor samples using a high-throughput circRNA microarray. Bioinformatic analyses were applied to study these differentially expressed circRNAs. Furthermore, qRT-PCR was performed to confirm these results. The circ-FOXM1 expression levels as well as clinicopathological significance were evaluated in primary RCC clinical specimens and RCC cell lines. In vitro knockdown of circ-FOXM1 in RCC cell lines was used to determine its effect on cellular proliferation, migration, and invasion.
RESULTS: Here we identified 528 differentially expressed circRNAs in primary metastatic ccRCC as compared with primary nonmetastatic ccRCC, of which 282 were significantly upregulated and 246 were downregulated. Differential circRNAs expression between the two groups were validated by qRT-PCR assay. Bioinformatics was employed to predict the interaction of circRNAs and mRNAs in metastatic ccRCC. We further characterized one circRNA hsa_circ_0025036 derived from the FOXM1 gene and termed it as circ-FOXM1. The expression of circ-FOXM1 is often upregulated in primary metastatic ccRCC as compared with primary non-metastatic ccRCC. The level of circ-FOXM1 was observed as an independent prognostic marker for overall survival of patients with ccRCC. Moreover, circ-FOXM1 promotes migratory, invasive, and metastasis capacities of ccRCC cells.
CONCLUSIONS: Overall, the differential expression of multiple circRNAs and their clinical significance in metastatic ccRCC tissues as revealed by our study suggests that circ-FOXM1 is a novel metastatic factor and prognostic marker in ccRCC, we propose that circRNA-FOXM1 could be used as a potential target in metastatic ccRCC therapy.
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MP88-13 TUMOR SUPPRESSOR TSC1 IS A NEW HSP90 COCHAPERONE THAT FACILITATES FOLDING OF KINASE AND NON-KINASE CLIENTS
Mark Woodford, Rebecca Sager, Adam Blanden, Stewart Loh, Syracuse, NY; David Gutmann, St. Louis, MO; Oleg Shapiro, Dimitra Bourboulia, Syracuse, NY; Michael Wong, St. Louis, MO; Gennady Bratslavsky, Mehdi Mollapour*, Syracuse, NY INTRODUCTION AND OBJECTIVES: Mutation of either TSC1 or TSC2 causes tuberous sclerosis, a multisystem genetic syndrome that can lead to formation of benign tumors in the kidneys, lungs, and other organs and has also been linked to epilepsy and autism. The tumor suppressors Tsc1 and Tsc2 form the tuberous sclerosis complex (TSC), a regulator of mTOR activity. Tsc1 stabilizes Tsc2; however the precise mechanism remains elusive. Molecular chaperones such as heat shock protein-90 (Hsp90) are essential for the stability and activation of numerous signaling proteins, including tumor suppressors. The objective of this work was to determine the role of Hsp90 in the stability and activity of TSC. We hypothesize that Hsp90 mediates TSC formation and thus is essential for the stability of Tsc2.
METHODS: Tsc1-FLAG and Tsc2-FLAG were transiently expressed and isolated from HEK293 cells. Interacting proteins were identified by co-immunoprecipitation. Hsp90 chaperone function is coupled to its ATPase activity. We have developed an assay to measure this activity by determining the rate of ATP breakdown and inorganic phosphate production. Hsp90 was isolated from WT and TSC1-/-mice and assayed for ATPase activity in vitro.
RESULTS: Tsc2 interacts with the molecular chaperone Hsp90 both in vitro and in vivo. Treatment of HEK293 cells with Hsp90 inhibitors such as ganetespib or SNX2112 caused ubiquitination and proteasomal degradation of Tsc2; therefore Tsc2 is a new client of Hsp90. However, Tsc1 stability does not depend on Hsp90. Tsc1 potently decelerates Hsp90 ATPase activity and facilitates the interaction of Tsc2 and other clients with Hsp90. We also showed that Tsc1 competes with the activating co-chaperone Aha1 for binding to Hsp90, providing a reciprocal regulatory mechanism for chaperoning of kinase and non-kinase clients.
CONCLUSIONS: Tsc1 interacts with Tsc2 and protects Tsc2 from degradation. Many pathogenic mutations of Tsc2 destabilize the protein. Our data suggest that lack of interaction of pathogenic Tsc2 mutants with Tsc1 and consequently Hsp90 lead to their degradation. Further, these newly elucidated roles of Tsc1 and Tsc2 suggest a potential mechanism for the observed differences between TSC1 and TSC2 mutant disease. In the absence of Tsc2, Tsc1 will still perform its critical role as a co-chaperone of Hsp90. However when Tsc1 is lost, the stability of both Tsc2 and many other Hsp90 clients is dramatically reduced, leading to a different phenotypic manifestation. 
MP88-14 CANCER STEM CELL FEATURE CAN INDUCE RESISTANCE TO MTOR INHIBITORS VIA THE NOTCH PATHWAY IN RENAL CELL CARCINOMAS
Kazuyuki Numakura*, Akita, Japan; Jesse Novac, Jean-Christophe Pignon, Toni Choueiri, Sabina Signoretti, Boston, MA INTRODUCTION AND OBJECTIVES: Previous studies have shown that treatment with an mTOR inhibitor (mTORi) is effective against renal cell carcinomas (RCCs), but with limited efficacy and durability. The concept of a cancer stem cell may explain treatment failures in advanced RCCs, but there is no evidence to support this, especially regarding mTORi resistance. Notch, which converts aldehydes to carboxylic acids in the cell membrane, may contribute to the generation of a drug-tolerant tumor cell population. In this study, the relationship between cancer stem cell characteristics and Notch activity was assessed in RCC cells with acquired resistance to mTORi.
METHODS: Four RCC cell lines (786-O, A-498, 769-P, and UMRC-3) with the VHL gene anomaly were analyzed for IC50 values of e1202 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 
